Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhIL-15 + nivolumab + ipilimumab
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
rhIL-15 + nivolumab + ipilimumab is a combination immunotherapy regimen being evaluated by the National Cancer Institute (NCI) for the treatment of metastatic or treatment-refractory solid tumors. The regimen consists of recombinant human interleukin-15 (rhIL-15), a cytokine that stimulates the activation and expansion of CD8+ T cells and natural killer (NK) cells, combined with two immune checkpoint inhibitors: nivolumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1), and ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). By combining a stimulatory cytokine with the blockade of two distinct inhibitory checkpoints, the therapy aims to enhance the immune system's ability to recognize and eliminate cancer cells. Clinical evaluation in a Phase 1 trial (NCT03388632) focused on determining the maximum tolerated dose and safety profile in patients with advanced refractory cancers.
- Brand names
- OpdivoYervoy
- Other names
- rhIL-15 in combination with nivolumab and ipilimumabrhIL15 in combination with nivolumab and ipilimumabrhIL 15 in combination with nivolumab and ipilimumabIL-15 + nivolumab + ipilimumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on rhIL-15 + nivolumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhIL-15 + nivolumab + ipilimumab.